Daunorubicin · Daunorubicin Hydrochloride

What is Daunorubicin?

Daunorubicin is an anthracycline antineoplastic antibiotic that exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, inhibiting DNA replication and repair and RNA and protein synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Daunorubicin Hydrochloride, Daunomycin

Drug type

Small molecule

Targets

DNA

Mechanism

Cytotoxic, directed at DNA

Pathways

DNA replication, DNA repair, RNA synthesis, protein synthesis

Therapy area

Oncology

Developer

Wyeth Ayerst

In trials of

SNDX

FDA status

Approved as Daunorubicin Hydrochloride (December 19, 1979), NDA050484 · FDA label

✅ FDA-approved uses

• Remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults
• Remission induction in acute lymphocytic leukemia of children and adults

From the indications section of the FDA label (version of Feb 15, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaAMLAML With Gene MutationsAML, AdultLeukemia

Sources

• FDA label Daunorubicin Hydrochloride (2024-02-15), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03013998
• ClinicalTrials.gov NCT03013998
• ClinicalTrials.gov NCT06313437

Updated Oct 3, 2026.